Shengdi Investment

Shengdi Investment is the professional venture capital and private equity arm of Jiangsu Hengrui Pharmaceuticals, one of China's largest and most prominent pharmaceutical companies. Established in 2021 and headquartered in Shanghai, the firm focuses on strategic investments across the life sciences sector, including innovative drug discovery, medical devices, and synthetic biology. Shengdi Investment plays a critical role in the broader Hengrui ecosystem by identifying and funding high-potential biotech startups that align with the parent company's long-term growth strategy. The firm typically leads or participates in Series B and C financing rounds, leveraging Hengrui's extensive industrial expertise and R&D infrastructure to support its portfolio companies. Notable investments include Novamab Biopharmaceuticals, Coherent Biopharma, and Drug Farm.